Free Trial
Your Rate Never Goes Up! Save $100 a Year on MarketBeat All Access
Upgrade Now
Claim MarketBeat All Access Sale Promotion
NASDAQ:ETON

Eton Pharmaceuticals Q3 2018 Earnings Results & Report

Eton Pharmaceuticals logo
$50.02 +0.72 (+1.46%)
Closing price 10/22/2026 04:00 PM Eastern
Extended Trading
$50.63 +0.61 (+1.23%)
As of 09:09 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Eton Pharmaceuticals reported Q3 2018 earnings on December 20, 2018. The company reported EPS of -$0.65.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q3 2018
Report Date
Time
Before Market Opens

Eton Pharmaceuticals EPS Results

Actual EPS
-$0.65
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A
EPS Beat Rate
1 of last 8 quarters

Eton Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Eton Pharmaceuticals' Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Q3 2026 Earnings Report

Conference Call Resources

Eton Pharmaceuticals Q3 2018 Earnings FAQ

Eton Pharmaceuticals (NASDAQ:ETON) reported earnings of -$0.65 per share for Q3 2018. The report was announced on Thursday, December 20, 2018.

Eton Pharmaceuticals' next earnings date is estimated for Thursday, November 5, 2026. MarketBeat tracks confirmed and estimated earnings dates for Eton Pharmaceuticals on the company's earnings history page.

Eton Pharmaceuticals Earnings Headlines

Eton Pharmaceuticals Has Stronger Earnings And A Little Valuation Cushion
 |  seekingalpha.comhttps://seekingalpha.com/article/4956789-eton-pharmaceuticals-has-stronger-earnings-and-little-valuation-cushion
Contrasting Eli Lilly and Company (NYSE:LLY) & Eton Pharmaceuticals (NASDAQ:ETON)
October 23 at 2:15 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31148292
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.tc pixel
October 23 at 1:00 AM  |  Chaikin Analytics (Ad)
Eton Pharmaceuticals (ETON) Stock Still Looks Rich Despite Its New Seizure Drug License
October 22 at 10:52 PM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/eton-pharmaceuticals-eton-stock-still-191353296.html
HC Wainwright Reaffirms "Buy" Rating for Eton Pharmaceuticals (NASDAQ:ETON)
October 16, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31123891
Eton Pharmaceuticals, Inc. and Aquestive Therapeutics, Inc. Announce Exclusive U.S. Licensing Agreement for Libervant® Buccal Film
October 14, 2026  |  marketscreener.comM
See More Eton Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Eton Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eton Pharmaceuticals and other key companies, straight to your email.

About Eton Pharmaceuticals

Eton Pharmaceuticals (NASDAQ:ETON) is a specialty pharmaceutical company focused on developing and commercializing treatments for rare diseases and other conditions with limited therapeutic options. The company generally pursues products that address unmet medical needs, including medicines for pediatric and orphan indications.

Eton’s commercial portfolio has included Alkindi Sprinkle, an oral hydrocortisone formulation used as replacement therapy in young children with adrenal insufficiency, and Eprontia, an oral solution formulation of topiramate. The company has also marketed hospital products such as Biorphen, an injectable phenylephrine product, and Rezipres, an injectable ephedrine sulfate product. Its portfolio may include products developed internally as well as products acquired or licensed from other pharmaceutical companies.

Founded in 2017, Eton is based in the United States and primarily serves the U.S. pharmaceutical market. The company works with external partners for aspects of product development, manufacturing and commercialization, while concentrating its own resources on identifying, obtaining regulatory approval for and commercializing specialized medicines. Eton Pharmaceuticals is led by Chief Executive Officer Sean Brynjelsen, who co-founded the company.

View Eton Pharmaceuticals Profile
Earnings Tools